MedTrace Logo

A Phase 1, Study of the Safety and Tolerability of ALV003 in Healthy Adult Volunteers and Subjects With Well-Controlled Celiac Disease

NCT00626184 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 28

Last updated 2009-08-18

No results posted yet for this study

Summary

To assess safety and tolerability of ALV003 in healthy volunteers and patients with Celiac Disease

Conditions

Interventions

DRUG

4 dose levels of ALV003

4 dose levels of ALV003 vs placebo

Sponsors & Collaborators

  • Alvine Pharmaceuticals Inc.

    lead INDUSTRY

Principal Investigators

  • Vijaya Pratha, MD · Clinical Applications Laboratory Inc.

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2008-02-29
Primary Completion
2008-05-31
Completion
2008-07-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00626184 on ClinicalTrials.gov